Vivanza Biosciences Limited (BOM:530057)
1.700
+0.030 (1.80%)
At close: Oct 16, 2026
Vivanza Biosciences Revenue
Vivanza Biosciences had revenue of 96.63M INR in the quarter ending June 30, 2026, with 7.88% growth. This brings the company's revenue in the last twelve months to 1.17B, up 733.83% year-over-year. In the fiscal year ending March 31, 2026, Vivanza Biosciences had annual revenue of 1.16B with 1,451.72% growth. That makes Vivanza Biosciences the 36,383rd largest company in the world by revenue and 3,034th in India.
Revenue (ttm)
1.17B
Revenue Growth
+733.83%
P/S Ratio
0.06
Revenue / Employee
194.55M
Employees
6
Market Cap
68.00M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.16B | 1.08B | 1,451.72% |
| Mar 31, 2025 | 74.72M | -204.18M | -73.21% |
| Mar 31, 2024 | 278.89M | 97.35M | 53.62% |
| Mar 31, 2023 | 181.54M | 69.55M | 62.10% |
| Mar 31, 2022 | 111.99M | 12.60M | 12.67% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Beryl Drugs | 213.23M |
| Fabino Enterprises | 208.42M |
| Brawn Biotech | 172.59M |
| Unjha Formulations | 152.79M |
| Decipher Labs | 138.51M |
| Desh Rakshak Aushdhalaya | 66.33M |
| Ganga Pharmaceuticals | 28.28M |
| Emmessar Biotech & Nutrition | 23.78M |